Amgen says experimental obesity drug has promising durability
LOS ANGELES, Dec 3 (Reuters) – Amgen Inc’s (AMGN.O) experimental obesity drug demonstrated promising durability trends in an early trial, paving the way for a larger mid-stage study early next … Read More